Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review
Daniela Malafaia, Hélio M. T. Albuquerque, Artur M. S. Silva
European Journal of Medicinal Chemistry (2021) Vol. 214, pp. 113209-113209
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
Xiangqian Li, Xiaowei Li, Fang Liu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10581-10605
Closed Access | Times Cited: 104
Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
Zdeněk Fišar
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1676-1676
Open Access | Times Cited: 53
Mechanisms of action of coffee bioactive compounds – a key to unveil the coffee paradox
Fernanda Machado, Manuel A. Coimbra, M. Dolores del Castillo, et al.
Critical Reviews in Food Science and Nutrition (2023) Vol. 64, Iss. 28, pp. 10164-10186
Closed Access | Times Cited: 28
Dual Inhibitors of Amyloid-β and Tau Aggregation with Amyloid-β Disaggregating Properties: Extended In Cellulo, In Silico, and Kinetic Studies of Multifunctional Anti-Alzheimer’s Agents
Anna Pasieka, Dawid Panek, Natalia Szałaj, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 11, pp. 2057-2068
Open Access | Times Cited: 53
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders
Claudiu T. Supuran
Journal of Enzyme Inhibition and Medicinal Chemistry (2021) Vol. 36, Iss. 1, pp. 1702-1714
Open Access | Times Cited: 43
Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
Anna Sampietro, F. Javier Pérez-Areales, Paula Felippe Martinez, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 545-545
Open Access | Times Cited: 33
Recent Trends and Practices Toward Assessment and Rehabilitation of Neurodegenerative Disorders: Insights From Human Gait
Ratan Das, Sudip Paul, Gajendra Kumar Mourya, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 31
Carbamate as a potential anti‐Alzheimer's pharmacophore: A review
Yash Pal Singh, Navneet Kumar, Brijesh Singh Chauhan, et al.
Drug Development Research (2023) Vol. 84, Iss. 8, pp. 1624-1651
Closed Access | Times Cited: 17
Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease
Mahmoud Nabawy Mahmoud Khattab, Heba M. Mansour, HalaM Fawzy, et al.
Neural Regeneration Research (2021) Vol. 17, Iss. 9, pp. 1913-1913
Open Access | Times Cited: 41
Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer’s Disease?
Giuseppe Di Natale, Giuseppina Sabatino, Michele F. M. Sciacca, et al.
Molecules (2022) Vol. 27, Iss. 16, pp. 5066-5066
Open Access | Times Cited: 24
Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease
Michele Tonelli, Marco Catto, Raimon Sabaté, et al.
European Journal of Medicinal Chemistry (2023) Vol. 250, pp. 115169-115169
Open Access | Times Cited: 15
In Silico Drug Design and Analysis of Dual Amyloid-Beta and Tau Protein-Aggregation Inhibitors for Alzheimer’s Disease Treatment
Nisha Job, Venkatesan S. Thimmakondu, Krishnan Thirumoorthy
Molecules (2023) Vol. 28, Iss. 3, pp. 1388-1388
Open Access | Times Cited: 11
The Prophylactic and Multimodal Activity of Two Isatin Thiosemicarbazones against Alzheimer’s Disease In Vitro
Barbara Mavroidi, Archontia Kaminari, Dimitris Matiadis, et al.
Brain Sciences (2022) Vol. 12, Iss. 6, pp. 806-806
Open Access | Times Cited: 19
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)
José G. Fernández‐Bolaños, Óscar López
Expert Opinion on Therapeutic Patents (2022) Vol. 32, Iss. 8, pp. 913-932
Closed Access | Times Cited: 18
Dialkylation of Alkenes to Fluorinated δ-Lactams Enabled by Nickel-Electron-Shuttle Catalysis
Sunfeng Ye, Bangkui Yu, Hanmin Huang
Organic Letters (2025)
Closed Access
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies
Yunkwon Nam, Soo Jung Shin, Vijay Kumar, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access
A covalent strategy to target intrinsically disordered proteins: Discovery of novel tau aggregation inhibitors
László Petri, Péter Ábrányi‐Balogh, Darius Vagrys, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114163-114163
Open Access | Times Cited: 15
Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway
Salma M. Eraky, Nehal M. Ramadan, Nada F. Abo El‐Magd
International Journal of Biological Macromolecules (2022) Vol. 227, pp. 1119-1131
Closed Access | Times Cited: 15
Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (BChE) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer’s Disease
Lei Wang, Tian‐Yu Sun, Zhenqi Wang, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 17, pp. 3226-3248
Closed Access | Times Cited: 9
Recent advancements in the therapeutic approaches for Alzheimer's disease treatment: Current and future perspective
Amit Sharma, Santosh Rudrawar, Sandip B. Bharate, et al.
RSC Medicinal Chemistry (2024)
Open Access | Times Cited: 3
Steroid–Quinoline Hybrids for Disruption and Reversion of Protein Aggregation Processes
Hélio M. T. Albuquerque, Raquel Nunes da Silva, Marisa Pereira, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 3, pp. 443-448
Open Access | Times Cited: 12
Dual modulators of aggregation and dissociation of amyloid beta and tau: In vitro, in vivo, and in silico studies of Uncaria rhynchophylla and its bioactive components
Sujin Kim, Yunkwon Nam, Soo Jung Shin, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113865-113865
Open Access | Times Cited: 12
Evaluation of binding mechanism of dietary phytochemical, capsaicin, with human transferrin: targeting neurodegenerative diseases therapeutics
Mohammed Alrouji, Fahad A. Alhumaydhi, Kumar Venkatesan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Discovery of Dual Aβ/Tau Inhibitors and Evaluation of Their Therapeutic Effect on a Drosophila Model of Alzheimer’s Disease
Annachiara Gandini, Ana Elisa Gonçalves, Silvia Strocchi, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 23, pp. 3314-3329
Open Access | Times Cited: 11
Genipin and pyrogallol: Two natural small molecules targeting the modulation of disordered proteins in Alzheimer's disease
Sujin Kim, Da Gyeong Hyun, Yunkwon Nam, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115770-115770
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top